

# Idylla™ EGFR Mutation Assay





### **EGFR**

Lung cancer is the most common cancer worldwide, contributing for 13% of all cancer types<sup>1</sup>. 85% of lung cancers are non-small cell lung cancers (NSCLC), of which histologically adenocarcinoma is the most prevalent<sup>2</sup>. The prevalence of EGFR mutations in NSCLC is 10-15% of Western and up to 50% of Asian patients<sup>3</sup>. The most common EGFR mutations are the L858R mutation in exon 21 and deletions at exon 19<sup>4</sup>.

Idylla<sup>™</sup>, Biocartis' fully automated, real-time PCR based system, offers fast and easy access to high quality biomarker data.

The Idylla™ EGFR Mutation Assay allows detection of EGFR mutations directly from formalin-fixed paraffinembedded (FFPE) tissue sections in approx. 2.5 hours with less than 2 minutes hands-on time.

The Idylla™ EGFR Mutation Assay is capable of detecting 53 relevant mutations in exons 18, 19, 20 and 21; at an average sensitivity of 1-5% based on research data.

The game-changing real-time PCR based technology uses a unique combination of PlexPrime<sup>™</sup> and PlexZyme<sup>™</sup>, which allows very high sensitivity and specificity combined with high multiplexing capability.\*

"Idylla is a cost-effective solution ensuring accurate and fast detection of all relevant mutations"

Prof. Giancarlo Troncone,
Department of Public Health, Anatomic Pathology Unit,
University of Napoli Federico II School of Medicine,
Research Standard (Napoli, Italy)

## About Idylla™ EGFR Mutation Assay

Idylla<sup>™</sup>, Biocartis' fully automated, real-time PCR-based system combines:



#### **OUTSTANDING EASE OF USE**

- Fully automated sample processing
- Directly from FFPE tissue samples
- No manual deparaffinization required
- All reagents integrated within the cartridge
- Contamination-controlled design



#### **ACCURACY**

- High specificity and high average sensitivity of 1-5% based on research data
- Detection of 53 relevant mutations in one cartridge



#### **SPEED**

- Less than 2 minutes hands-on-time
- Total turnaround time approx. 2.5 hours



#### **CONNECTIVITY**

• Remote assistance, monitoring and upgrading




For Research Use Only



outstanding ease-of-use and short turnaround time.







### Highly standardized

The Idylla™ EGFR Mutation Assay, performed on the Biocartis Idylla™ System, is a molecular assay for the qualitative detection of exon 18 (G719A/ S/C), exon 21 (L858R, L861Q), exon 20 (T790M, S768I) mutations, exon 19 deletions and exon 20 insertions in the EGFR oncogene.

The Idylla™ EGFR Mutation Assay, from sampleto-result, starts with formalin-fixed, paraffinembedded (FFPE) human tissue from non-small cell lung cancers to liberate DNA for subsequent real-time PCR amplification and detection.

Exon 18	c.2156G>C (G719A)
	c.2155G>A (G719S)
	c.2155G>T (G719C)
	c.2154_2155delinsTT (G719C)
Exon 19	c.2239_2248delinsC (del9)
	c.2239_2247del (del9)
	c.2238_2248delinsGC (del9)
	c.2240_2248del (del9)
	c.2239_2251delinsC (del12)
	c.2240_2251del (del12)
	c.2235_2249del (del15)
	c.2236_2250del (del15)
	c.2239_2253del (del15)
	c.2237_2251del (del15)
	c.2235_2252delinsAAT (del15)
	c.2240_2254del (del15)
	c.2238_2252del (del15)
	c.2237_2252delinsT (del15)
	c.2234_2248del (del15)
	c.2236_2253delinsCTA (del15)
	c.2237_2253delinsTA (del15)
	c.2237_2253delinsTC (del15)
	c.2235_2251delinsAG (del15)
	c.2236_2253delinsCAA (del15)
	c.2238_2252del (del15)
	c.2230_2249delinsGTCAA (del15)
	c.2240_2257del (del18)
	c.2237_2255delinsT (del18)
	c.2239_2258delinsCA (del18)
	c.2237_2254del (del18)
	c.2238_2255del (del18)
	c.2239_2256del (del18)
	c.2236_2253del (del18)
	c.2237_2257delinsTCT (del18)
	c.2236_2255delinsAT (del18)
	c.2236_2256delinsATC (del18)
	c.2237_2256delinsTT (del18)
	c.2237_2256delinsTC (del18)
	c.2235_2255delinsGGT (del18)
	c.2238_2258del (del21)
	c.2236-2256del (del21)
	c.2253-2276del (del24)
Exon 20	c.2369C>T (T790M)
	c.2303G>T (S768I)
	c.2308_2309insGCCAGCGTG (insASV9)
	c.2308_2311insCCAGCGTGGAT (insASV11)
	c.2311_2312insGCGTGGACA (insSVD)
	c.2310_2311insGGT (insG)
	c.2319_2320insCAC (insH)
Exon 21	c.2573T>G (L858R)
	c.2573_2574delinsGT (L858R)
	c.2573_2574delinsGA (L858R)
	c.2582T>A (L861Q)
	acting as Sample Processing Control)
	PE tissue section ≥10% tumor cells acro-dissection is needed
approx. 2.5 h	nours

Allele detection

Sample type

turnaround

Total

time

<sup>1.</sup> N. Navani, PhD, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomized controlled trial. Lancet Respir Med (2015)

American Cancer Society. Global Cancer Facts & Figures 2nd Edition
 W. A. Cooper et al. Molecular biology of lung cancer. J Thorac Dis (2013)

<sup>4.</sup> NCCN Guidelines Version 4.2016 Non-Small Cell Lung Cancer



#### Order information

ldylla™ EGFR Mutation Assay RUO	6 cartridges/box	Catalog# A0061/6		
ldylla™ Instrument CE-IVD	1 unit	Catalog# P0010		
ldylla™ Console CE-IVD	1 unit	Catalog# P1010		

Biocartis NV Generaal De Wittelaan 11 B3 2800 Mechelen - Belgium T+3215632888

customerservice@biocartis.com www.biocartis.com

#### NOTICE TO PURCHASER

\*This Idylla™ EGFR Mutation Assay contains PlexZyme™ and PlexPrime™ technology covered by patents granted and pending in certain jurisdictions, which are supplied under license of SpeeDx Pty Ltd.

Biocartis trademark and logo are trademarks belonging to Biocartis and are used and registered in Europe. Idylla is a registered trademark in the United States and other countries. Idylla trademark and logo are used trademarks belonging to Biocartis.

PlexZyme<sup>™</sup> and PlexPrime<sup>™</sup> are trademarks of SpeeDx Pty Ltd.

Idylla<sup>™</sup> EGFR Mutation Assay is intended for Research Use Only. Not for sale in the USA and Canada.

Ref: EGFR20160515

For Research Use Only

